CA2426117A1 - Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe - Google Patents

Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe Download PDF

Info

Publication number
CA2426117A1
CA2426117A1 CA002426117A CA2426117A CA2426117A1 CA 2426117 A1 CA2426117 A1 CA 2426117A1 CA 002426117 A CA002426117 A CA 002426117A CA 2426117 A CA2426117 A CA 2426117A CA 2426117 A1 CA2426117 A1 CA 2426117A1
Authority
CA
Canada
Prior art keywords
thiazolidine
pyridyl
ethoxy
benzyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002426117A
Other languages
English (en)
Inventor
Prabhakar Chebiyyam
Ramabhadra Sarma Mamillapalli
Vyas Krishnamurthi
Vishnuvardhan Reddy Seella
Om Reddy Gaddam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2426117A1 publication Critical patent/CA2426117A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des nouvelles formes polymorphes/pseudo-polymorphes de 5-[4-[2[N-méthyl-N-(2-pyridyl)amino]éthoxy]benzyl] thiazolidine-2,4-dione maléate de formule (I). L'invention concerne également une composition pharmaceutique renfermant les nouvelles formes polymorphes ou un mélange de celles-ci et un adjuvant acceptable sur le plan pharmaceutique. Les formes polymorphes selon l'invention sont plus actives, comme agent anti-diabétique, que le 5-[4-[2-[N-(2-méthyl-N-(2-pyridyl)amino]éthoxy]benzyl] thiazolidine-2,4-dione maléate connu jusqu'à présent.
CA002426117A 2000-09-26 2001-09-25 Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe Abandoned CA2426117A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN805CH2000 2000-09-26
IN805/MAS/00 2000-09-26
PCT/US2001/029896 WO2002026737A1 (fr) 2000-09-26 2001-09-25 Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe

Publications (1)

Publication Number Publication Date
CA2426117A1 true CA2426117A1 (fr) 2002-04-04

Family

ID=29266775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002426117A Abandoned CA2426117A1 (fr) 2000-09-26 2001-09-25 Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe

Country Status (15)

Country Link
EP (1) EP1322647A1 (fr)
JP (1) JP2004509961A (fr)
AU (1) AU9123201A (fr)
BR (1) BR0114196A (fr)
CA (1) CA2426117A1 (fr)
CZ (1) CZ2003864A3 (fr)
HU (1) HUP0301161A3 (fr)
IL (1) IL155036A0 (fr)
MX (1) MXPA03002580A (fr)
NO (1) NO324968B1 (fr)
NZ (1) NZ525498A (fr)
PL (1) PL360661A1 (fr)
SK (1) SK3752003A3 (fr)
WO (1) WO2002026737A1 (fr)
ZA (1) ZA200303223B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
PL351684A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
WO2004062667A1 (fr) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Forme amorphe du maleate de rosiglitazone et procede de preparation
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (fr) * 2003-04-18 2004-11-03 CHEMI S.p.A. Formes polymorphes de maléate de rosiglitatone
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
WO2005095390A2 (fr) * 2004-03-31 2005-10-13 Sandoz Ag Nouveau co-precipite
EP1757603A4 (fr) * 2004-05-11 2008-06-25 Santen Pharmaceutical Co Ltd Agent thérapeutique pour une affection de kératoconjonctivite
JP2005350451A (ja) * 2004-05-11 2005-12-22 Santen Pharmaceut Co Ltd 角結膜障害治療剤
CZ2004844A3 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (fr) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Procédé de préparation de formes galéniques solides de maléate de rosiglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
EP0844997A1 (fr) * 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Nouvelles formes polymorphes de la troglitazone ayant une activite anti-diabetique augmentee et procede pour leur preparation
JP2000514041A (ja) * 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
PL351684A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
BR0009934A (pt) * 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico

Also Published As

Publication number Publication date
NO324968B1 (no) 2008-01-14
NO20031356L (no) 2003-05-26
SK3752003A3 (sk) 2005-03-04
MXPA03002580A (es) 2003-10-15
HUP0301161A2 (hu) 2003-11-28
WO2002026737A1 (fr) 2002-04-04
HUP0301161A3 (en) 2005-04-28
PL360661A1 (en) 2004-09-20
NZ525498A (en) 2004-11-26
ZA200303223B (en) 2004-07-26
WO2002026737A8 (fr) 2003-11-06
AU9123201A (en) 2002-04-08
JP2004509961A (ja) 2004-04-02
EP1322647A1 (fr) 2003-07-02
IL155036A0 (en) 2003-10-31
NO20031356D0 (no) 2003-03-25
CZ2003864A3 (cs) 2004-01-14
BR0114196A (pt) 2003-07-22

Similar Documents

Publication Publication Date Title
CA2426117A1 (fr) Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe
WO2000063191A1 (fr) Nouvelles formes polymorphes d'un agent antidiabetique: procede de preparation et composition pharmaceutique contenant ces dernieres
CZ20013711A3 (cs) Nové polymorfní formy antidiabetických činidel, způsob jejich přípravy a farmaceutické prostředky s jejich obsahem
US7241895B2 (en) Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2002028857A1 (fr) Polymorphes de chlorhydrates de pioglitazone et leur utilisation en tant qu'antidiabetiques
AU2001291232B8 (en) Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
EP1623984A1 (fr) Polymorphe I du sel de potassium de 5-[4-[[3-methyle-4-oxo-3,4-dihydroquinazoline-2yl]methoxy]benzyle]thiazolidine-2,4-dione
AU2001291232A1 (en) Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US7678916B2 (en) Process
US6528507B1 (en) Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
KR20070113328A (ko) 5-[4-[2-[엔-메틸-엔-(2-피리딜)아미노]에톡시]벤질]티아졸리딘 4-디온 말레이트의 신규의 다형상 및 그제조방법
KR20070116188A (ko) 5-[4-[2-[엔-메틸-엔-(2-피리딜)아미노]에톡시]벤질]티아졸리딘 4-디온 말레이트의 신규의 다형상 및 그제조방법
KR20070116189A (ko) 5-[4-[2-[엔-메틸-엔-(2-피리딜)아미노]에톡시]벤질]티아졸리딘 4-디온 말레이트의 신규의 다형상 및 그제조방법
WO2003066612A1 (fr) Nouvelles formes polymorphes d'agents bicycliques antidiabetiques, leur procede de preparation et compositions pharmaceutiques les contenant
JP2005523300A5 (fr)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued